835 related articles for article (PubMed ID: 26848860)
1. Therapeutic opportunities in Ewing sarcoma: EWS-FLI inhibition via LSD1 targeting.
Theisen ER; Pishas KI; Saund RS; Lessnick SL
Oncotarget; 2016 Apr; 7(14):17616-30. PubMed ID: 26848860
[TBL] [Abstract][Full Text] [Related]
2. Blocking the road, stopping the engine or killing the driver? Advances in targeting EWS/FLI-1 fusion in Ewing sarcoma as novel therapy.
Kovar H
Expert Opin Ther Targets; 2014 Nov; 18(11):1315-28. PubMed ID: 25162919
[TBL] [Abstract][Full Text] [Related]
3. BET bromodomain inhibitors suppress EWS-FLI1-dependent transcription and the IGF1 autocrine mechanism in Ewing sarcoma.
Loganathan SN; Tang N; Fleming JT; Ma Y; Guo Y; Borinstein SC; Chiang C; Wang J
Oncotarget; 2016 Jul; 7(28):43504-43517. PubMed ID: 27259270
[TBL] [Abstract][Full Text] [Related]
4. Targeting the epigenetic readers in Ewing sarcoma inhibits the oncogenic transcription factor EWS/Fli1.
Jacques C; Lamoureux F; Baud'huin M; Rodriguez Calleja L; Quillard T; Amiaud J; Tirode F; Rédini F; Bradner JE; Heymann D; Ory B
Oncotarget; 2016 Apr; 7(17):24125-40. PubMed ID: 27006472
[TBL] [Abstract][Full Text] [Related]
5. Targeting the EWS-ETS transcriptional program by BET bromodomain inhibition in Ewing sarcoma.
Hensel T; Giorgi C; Schmidt O; Calzada-Wack J; Neff F; Buch T; Niggli FK; Schäfer BW; Burdach S; Richter GH
Oncotarget; 2016 Jan; 7(2):1451-63. PubMed ID: 26623725
[TBL] [Abstract][Full Text] [Related]
6. Reversible LSD1 inhibition interferes with global EWS/ETS transcriptional activity and impedes Ewing sarcoma tumor growth.
Sankar S; Theisen ER; Bearss J; Mulvihill T; Hoffman LM; Sorna V; Beckerle MC; Sharma S; Lessnick SL
Clin Cancer Res; 2014 Sep; 20(17):4584-97. PubMed ID: 24963049
[TBL] [Abstract][Full Text] [Related]
7. Mechanism and relevance of EWS/FLI-mediated transcriptional repression in Ewing sarcoma.
Sankar S; Bell R; Stephens B; Zhuo R; Sharma S; Bearss DJ; Lessnick SL
Oncogene; 2013 Oct; 32(42):5089-100. PubMed ID: 23178492
[TBL] [Abstract][Full Text] [Related]
8. Ecteinascidin 743 interferes with the activity of EWS-FLI1 in Ewing sarcoma cells.
Grohar PJ; Griffin LB; Yeung C; Chen QR; Pommier Y; Khanna C; Khan J; Helman LJ
Neoplasia; 2011 Feb; 13(2):145-53. PubMed ID: 21403840
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and structure-activity relationship studies of small molecule disruptors of EWS-FLI1 interactions in Ewing's sarcoma.
Tosso PN; Kong Y; Scher L; Cummins R; Schneider J; Rahim S; Holman KT; Toretsky J; Wang K; Üren A; Brown ML
J Med Chem; 2014 Dec; 57(24):10290-303. PubMed ID: 25432018
[TBL] [Abstract][Full Text] [Related]
10. Pharmaceutical Interference of the EWS-FLI1-driven Transcriptome By Cotargeting H3K27ac and RNA Polymerase Activity in Ewing Sarcoma.
Heisey DAR; Jacob S; Lochmann TL; Kurupi R; Ghotra MS; Calbert ML; Shende M; Maves YK; Koblinski JE; Dozmorov MG; Boikos SA; Benes CH; Faber AC
Mol Cancer Ther; 2021 Oct; 20(10):1868-1879. PubMed ID: 34315769
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of the oncogenic fusion protein EWS-FLI1 causes G
Zöllner SK; Selvanathan SP; Graham GT; Commins RMT; Hong SH; Moseley E; Parks S; Haladyna JN; Erkizan HV; Dirksen U; Hogarty MD; Üren A; Toretsky JA
Sci Signal; 2017 Oct; 10(499):. PubMed ID: 28974650
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic modeling optimizes inhibition of the 'undruggable' EWS-FLI1 transcription factor in Ewing Sarcoma.
Hong SH; Youbi SE; Hong SP; Kallakury B; Monroe P; Erkizan HV; Barber-Rotenberg JS; Houghton P; Üren A; Toretsky JA
Oncotarget; 2014 Jan; 5(2):338-50. PubMed ID: 24481407
[TBL] [Abstract][Full Text] [Related]
13. Catalytic inhibition of KDM1A in Ewing sarcoma is insufficient as a therapeutic strategy.
Romo-Morales A; Aladowicz E; Blagg J; Gatz SA; Shipley JM
Pediatr Blood Cancer; 2019 Sep; 66(9):e27888. PubMed ID: 31207107
[TBL] [Abstract][Full Text] [Related]
14. Proteasomal Degradation of the EWS-FLI1 Fusion Protein Is Regulated by a Single Lysine Residue.
Gierisch ME; Pfistner F; Lopez-Garcia LA; Harder L; Schäfer BW; Niggli FK
J Biol Chem; 2016 Dec; 291(52):26922-26933. PubMed ID: 27875302
[TBL] [Abstract][Full Text] [Related]
15. High-throughput RNAi screen in Ewing sarcoma cells identifies leucine rich repeats and WD repeat domain containing 1 (LRWD1) as a regulator of EWS-FLI1 driven cell viability.
He T; Surdez D; Rantala JK; Haapa-Paananen S; Ban J; Kauer M; Tomazou E; Fey V; Alonso J; Kovar H; Delattre O; Iljin K
Gene; 2017 Jan; 596():137-146. PubMed ID: 27760381
[TBL] [Abstract][Full Text] [Related]
16. Identification of Mithramycin Analogues with Improved Targeting of the EWS-FLI1 Transcription Factor.
Osgood CL; Maloney N; Kidd CG; Kitchen-Goosen S; Segars L; Gebregiorgis M; Woldemichael GM; He M; Sankar S; Lessnick SL; Kang M; Smith M; Turner L; Madaj ZB; Winn ME; Núñez LE; González-Sabín J; Helman LJ; Morís F; Grohar PJ
Clin Cancer Res; 2016 Aug; 22(16):4105-18. PubMed ID: 26979396
[TBL] [Abstract][Full Text] [Related]
17. EWS-FLI1 confers exquisite sensitivity to NAMPT inhibition in Ewing sarcoma cells.
Mutz CN; Schwentner R; Aryee DNT; Bouchard EDJ; Mejia EM; Hatch GM; Kauer MO; Katschnig AM; Ban J; Garten A; Alonso J; Banerji V; Kovar H
Oncotarget; 2017 Apr; 8(15):24679-24693. PubMed ID: 28160567
[TBL] [Abstract][Full Text] [Related]
18. Dual targeting of EWS-FLI1 activity and the associated DNA damage response with trabectedin and SN38 synergistically inhibits Ewing sarcoma cell growth.
Grohar PJ; Segars LE; Yeung C; Pommier Y; D'Incalci M; Mendoza A; Helman LJ
Clin Cancer Res; 2014 Mar; 20(5):1190-203. PubMed ID: 24277455
[TBL] [Abstract][Full Text] [Related]
19. Signature-based small molecule screening identifies cytosine arabinoside as an EWS/FLI modulator in Ewing sarcoma.
Stegmaier K; Wong JS; Ross KN; Chow KT; Peck D; Wright RD; Lessnick SL; Kung AL; Golub TR
PLoS Med; 2007 Apr; 4(4):e122. PubMed ID: 17425403
[TBL] [Abstract][Full Text] [Related]
20. PI3K/AKT signaling modulates transcriptional expression of EWS/FLI1 through specificity protein 1.
Giorgi C; Boro A; Rechfeld F; Lopez-Garcia LA; Gierisch ME; Schäfer BW; Niggli FK
Oncotarget; 2015 Oct; 6(30):28895-910. PubMed ID: 26336820
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
